Pre-clinical testing the effects of MALT1 inhibitor on endocrine resistant breast cancer
MALT1抑制剂对内分泌耐药乳腺癌的临床前测试
基本信息
- 批准号:10435975
- 负责人:
- 金额:$ 18.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-24 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:Adjuvant TherapyAromatase InhibitorsB-Cell LymphomasBCL10 geneBreast Cancer CellBreast Cancer PatientBreast Cancer TreatmentCASP8 geneCDK4 geneCancer EtiologyCell CycleCellsCessation of lifeChronic Lymphocytic LeukemiaClinicalClinical TrialsComplexDataDevelopmentDiseaseDisease ProgressionDoseEndocrineEstrogen ReceptorsEstrogen receptor positiveEstrogensFRAP1 geneFulvestrantGrowthGrowth Factor ReceptorsIn VitroLeadLifeLymphocyte ActivationLymphoid TissueLymphomaMammary NeoplasmsMediatingMucosa- associated lymphoid tissue lymphoma translocation protein-1MutateNeoplasm MetastasisNon-Hodgkin&aposs LymphomaOutcomePathway interactionsPatient-Focused OutcomesPatient-derived xenograft models of breast cancerPatientsPharmacologyPhase I Clinical TrialsPre-Clinical ModelPreclinical TestingProtein translocationRecurrent diseaseRefractoryRegulatory T-LymphocyteRelapseResistanceSignal PathwaySignal TransductionSignaling MoleculeTRAF6 geneTamoxifenTestingTimeToxic effectTumor ImmunityUnited StatesWomanantagonistbaseeffective therapyeffectiveness testingexperiencehormone therapyimprovedin vivoin vivo Modelinhibitorlarge cell Diffuse non-Hodgkin&aposs lymphomamalignant breast neoplasmmucosa-associated lymphoid tissue lymphomapatient derived xenograft modelpreclinical studyrecruitrelapse patientsresistance mechanismsmall moleculestandard of caresuccesstargeted treatmenttreatment strategytumorvirtual
项目摘要
Project Summary/Abstract
Breast cancer is the second leading cause of cancer death among women in the United States, and more than
70% of breast cancers are estrogen receptor-positive (ER+). Endocrine therapy has dramatically improved
survival of ER+ patients. However, approximately 40% of these patients relapse and die from metastases that
are refractory or resist endocrine therapy. Factors proposed to mediate this resistance include ER and ER co-
regulators, cell cycle signaling molecules and growth factor receptor pathways. Though clinical trials targeting
these factors show some success, the overall outcome is unsatisfactory. Therefore, discovering new targets of
endocrine resistance is a critical barrier to developing new breast cancer treatment strategies. Our preliminary
data indicate such a target Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein-1 (MALT1).
MALT1, originally identified in B-cell lymphomas, promotes development of a subset of diffuse large B cell
lymphomas and MALT lymphoma. Therapies targeting MALT1 for these lymphomas have been developed and
seem well-tolerated. Our preliminary studies show for the first time that MALT1 is increased in tamoxifen-resistant
breast tumor cells. Blocking MALT1 activity preferentially inhibits the growth of tamoxifen-resistant breast tumor
cells. In addition, blocking MALT1 renders tamoxifen-resistant cells responsive to tamoxifen. More importantly,
high MALT1 levels were strongly associated with tamoxifen resistance and poor patient survival. We hypothesize
that MALT1 mediates endocrine resistance and promotes growth of resistant breast tumor cells, and MALT1 is
a new target for treatment of endocrine-resistant breast cancer. In this application, we will use clinical compound
JNJ-67856633, the first MALT1 inhibitor being tested currently in phase 1 clinical trial, to define the effects of
MALT1 inhibitors on different subtypes of endocrine-resistant PDX breast tumors and to test the effectiveness
of MALT1 inhibitors in combination with different endocrine therapies on endocrine-resistant PDX models. The
results of this preclinical study will establish blocking MALT1 a new adjuvant therapy to restore the
responsiveness of endocrine-resistant breast cancers to endocrine therapy, and help initiate clinical trials to treat
patients suffering with the life-threating endocrine-resistant breast cancer.
项目摘要/摘要
乳腺癌是美国女性癌症死亡的第二大原因,超过
70%的乳腺癌是雌激素受体阳性(ER+)。内分泌治疗有了显著的改善
ER+患者的存活率。然而,这些患者中约有40%复发并死于
难治或抵抗内分泌治疗。提出的调节这种抗性的因素包括ER和ER共同作用。
调节因子、细胞周期信号分子和生长因子受体通路。通过临床试验靶向
这些因素显示了一些成功,但总体结果并不令人满意。因此,发现新的目标
内分泌抵抗是开发新的乳腺癌治疗策略的关键障碍。我们的预赛
有数据表明这种靶标为黏膜相关淋巴组织淋巴瘤易位蛋白-1(MALT1)。
最初在B细胞淋巴瘤中发现的MALT1促进弥漫性大B细胞亚群的发展
淋巴瘤和MALT淋巴瘤。针对这些淋巴瘤的MALT1靶向疗法已经开发出来,
看起来是可以容忍的。我们的初步研究首次显示MALT1对他莫昔芬的耐药性增加
乳腺肿瘤细胞。阻断MALT1活性优先抑制三苯氧胺耐药乳腺肿瘤的生长
细胞。此外,阻断MALT1使耐他莫昔芬的细胞对他莫昔芬产生反应。更重要的是,
MALT1水平高与他莫昔芬耐药和患者生存不良密切相关。我们假设
MALT1介导内分泌抵抗并促进耐药乳腺肿瘤细胞的生长,而MALT1是
治疗内分泌抵抗型乳腺癌的新靶点。在这个应用中,我们将使用临床化合物
JNJ-67856633,第一个正在测试的MALT1抑制剂,目前处于第一阶段临床试验,以确定
MALT1抑制剂治疗不同亚型内分泌抵抗型PDX乳腺肿瘤的疗效观察
在内分泌抵抗的PDX模型中,MALT1抑制剂与不同的内分泌治疗相结合。这个
这项临床前研究的结果将建立阻断MALT1的一种新的辅助治疗方法,以恢复
内分泌抵抗乳腺癌对内分泌治疗的反应性,并帮助启动治疗的临床试验
患有危及生命的内分泌抵抗型乳腺癌的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jianguo Liu其他文献
Jianguo Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jianguo Liu', 18)}}的其他基金
Role of RNA-binding protein in immune evasion of Mtb in macrophages
RNA结合蛋白在巨噬细胞中Mtb免疫逃避中的作用
- 批准号:
10634764 - 财政年份:2022
- 资助金额:
$ 18.69万 - 项目类别:
Role of RNA-binding protein in immune evasion of Mtb in macrophages
RNA结合蛋白在巨噬细胞中Mtb免疫逃避中的作用
- 批准号:
10511464 - 财政年份:2022
- 资助金额:
$ 18.69万 - 项目类别:
Pre-clinical testing the effects of MALT1 inhibitor on endocrine resistant breast cancer
MALT1抑制剂对内分泌耐药乳腺癌的临床前测试
- 批准号:
10579334 - 财政年份:2022
- 资助金额:
$ 18.69万 - 项目类别:
A new target for host-directed therapy against TB infection
针对结核感染的宿主定向治疗的新靶点
- 批准号:
10256733 - 财政年份:2020
- 资助金额:
$ 18.69万 - 项目类别:
A new target for host-directed therapy against TB infection
针对结核感染的宿主定向治疗的新靶点
- 批准号:
10057563 - 财政年份:2020
- 资助金额:
$ 18.69万 - 项目类别:
Mechanisms of IL28B genetic variation-mediated clearance of hepatitis C virus
IL28B基因变异介导的丙型肝炎病毒清除机制
- 批准号:
8445769 - 财政年份:2013
- 资助金额:
$ 18.69万 - 项目类别:
Mechanisms of IL28B genetic variation-mediated clearance of hepatitis C virus
IL28B基因变异介导的丙型肝炎病毒清除机制
- 批准号:
8732600 - 财政年份:2013
- 资助金额:
$ 18.69万 - 项目类别:
The role of tristetraprolin in control of breast cancer progression
三四脯氨酸在控制乳腺癌进展中的作用
- 批准号:
8221172 - 财政年份:2012
- 资助金额:
$ 18.69万 - 项目类别:
The role of tristetraprolin in control of breast cancer progression
三四脯氨酸在控制乳腺癌进展中的作用
- 批准号:
9079413 - 财政年份:2012
- 资助金额:
$ 18.69万 - 项目类别:
The role of tristetraprolin in control of breast cancer progression
三四脯氨酸在控制乳腺癌进展中的作用
- 批准号:
8860146 - 财政年份:2012
- 资助金额:
$ 18.69万 - 项目类别:
相似海外基金
Targeting Sphingosine-1-phosphate (S1P1) receptors for the treatment of Aromatase Inhibitors-induced Musculoskeletal Symptoms
靶向 1-磷酸鞘氨醇 (S1P1) 受体治疗芳香酶抑制剂引起的肌肉骨骼症状
- 批准号:
10668781 - 财政年份:2023
- 资助金额:
$ 18.69万 - 项目类别:
A value affirmation intervention for physical symptoms and medication adherence in breast cancer patients taking aromatase inhibitors
对服用芳香酶抑制剂的乳腺癌患者的身体症状和药物依从性进行价值肯定干预
- 批准号:
10063849 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
A value affirmation intervention for physical symptoms and medication adherence in breast cancer patients taking aromatase inhibitors
对服用芳香酶抑制剂的乳腺癌患者的身体症状和药物依从性进行价值肯定干预
- 批准号:
9884954 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
A value affirmation intervention for physical symptoms and medication adherence in breast cancer patients taking aromatase inhibitors
对服用芳香酶抑制剂的乳腺癌患者的身体症状和药物依从性进行价值肯定干预
- 批准号:
10311024 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
A value affirmation intervention for physical symptoms and medication adherence in breast cancer patients taking aromatase inhibitors
对服用芳香酶抑制剂的乳腺癌患者的身体症状和药物依从性进行价值肯定干预
- 批准号:
10535476 - 财政年份:2019
- 资助金额:
$ 18.69万 - 项目类别:
Basic research for the development of novel aromatase inhibitors against breast cancer
新型乳腺癌芳香酶抑制剂开发的基础研究
- 批准号:
18K07018 - 财政年份:2018
- 资助金额:
$ 18.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Aromatase Inhibitors and Weight Loss in Severely Obese Men with Hypogonadism
芳香酶抑制剂与患有性腺功能减退症的严重肥胖男性的减肥
- 批准号:
9942488 - 财政年份:2017
- 资助金额:
$ 18.69万 - 项目类别:
Aromatase Inhibitors and Weight Loss in Severely Obese Men with Hypogonadism
芳香酶抑制剂与患有性腺功能减退症的严重肥胖男性的减肥
- 批准号:
10412900 - 财政年份:2017
- 资助金额:
$ 18.69万 - 项目类别:
A motivational intervention to improve adherence to aromatase inhibitors in breast cancer survivors
提高乳腺癌幸存者对芳香酶抑制剂依从性的动机干预
- 批准号:
351822 - 财政年份:2016
- 资助金额:
$ 18.69万 - 项目类别:
Operating Grants
Impact of epigenetic markers of breast adipose tissue on the efficacy of aromatase inhibitors treatments.
乳房脂肪组织的表观遗传标记对芳香酶抑制剂治疗功效的影响。
- 批准号:
362464 - 财政年份:2016
- 资助金额:
$ 18.69万 - 项目类别:
Studentship Programs